Skip to main navigation Skip to search Skip to main content

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

  • ACT IV trial investigators
  • University of Zurich
  • University of California at San Francisco
  • Washington University St. Louis
  • Stanford University
  • Johns Hopkins University
  • Juravinski Cancer Centre
  • St. Joseph's Hospital and Medical Center, Phoenix
  • Dent Neurological Institute
  • John Theurer Cancer Center
  • Columbia University
  • University of Pittsburgh
  • University of Pennsylvania
  • Westmead Hospital
  • University of Calgary
  • IRCCS Fondazione Istituto Neurologico Carlo Besta - Milano
  • University of Toronto
  • German Cancer Research Center
  • Celldex Therapeutics, Inc
  • Duke University

Research output: Contribution to journal › Article › peer-review

989 Scopus citations

Fingerprint

Dive into the research topics of 'Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science